此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis

2026年11月9日 更新者:Orca Biosystems, Inc.

多中心1阶段1研究,用于使用Orca-Q的主要进行性多发性硬化症的同种异体造血细胞移植,这是一种源自动员外周血的工程供体移植

A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).

研究概览

详细说明

This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.

研究类型

介入性

注册 (估计的)

10

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:James S. McClellan, MD, PhD
  • 电话号码:650-246-9601
  • 邮箱:info@orcabio.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria (Recipient):

  1. Participants aged ≥18 and ≤65 years with PPMS

    a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision

  2. Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands

  3. EDSS between 2.0 and 5.5 inclusive

  4. Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)

  5. Eligibility criteria confirmed by the Eligibility Review Group

  6. Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0

  7. Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT

  8. Willing to undergo MAC preparative regimen

  9. Matched to either a related or unrelated donor as follows:

    1. Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    2. Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  10. Negative serum or urine β-HCG test in persons of childbearing potential

Exclusion Criteria:

  1. History of Progressive Multifocal Leukoencephalopathy

  2. Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:

    1. Renal insufficiency as defined by an estimated GFR <60 mL/minute
    2. Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
    3. Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
    4. Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
    5. Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
    6. Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
    7. Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
    8. Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
  3. History of smoking either tobacco or other herbal products in the last 3 months

  4. Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol

  5. HIV seropositive

  6. HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant

  7. HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy

  8. Participant has active uncontrolled infection

  9. Participant has demonstrated lack of compliance with prior medical care

  10. Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.

  11. Participants whose life expectancy is severely limited by illness other than multiple sclerosis

  12. Females who are pregnant or breast feeding

  13. Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol

  14. Inability to undergo an MRI scan

  15. Currently receiving treatment with investigational agents

  16. Positive for JC virus DNA in the CSF or blood during screening

  17. Known allergy or hypersensitivity to or intolerance of tacrolimus

  18. Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins

  19. Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:

    1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
    2. Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
  20. People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Orca-Q Graft with myeloablative conditioning regimen

Donor Orca-Q stem cell graft

Allogeneic (donor) stem cell graft

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

其他名称:
  • 白消安
  • 氟达拉滨
  • Thiotepa

Graft-versus-host disease (GVHD) prevention

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Severe acute graft-versus-host-disease-free survival
大体时间:Up to 6 months after infusion

Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse)

Up to 6 months after infusion

次要结果测量

结果测量
措施说明
大体时间
Event-Free Survival (EFS)
大体时间:Up to 24 months and at year 5 after Orca-Q infusion

Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death

Up to 24 months and at year 5 after Orca-Q infusion
Loss of Neurological Function or Relapse
大体时间:Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant

Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse

Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
Overall Survival (OS)
大体时间:From transplant through 5 years after transplant

Time in years from transplant to death from any cause

From transplant through 5 years after transplant
Treatment-Related Mortality (TRM)
大体时间:From start of alloHCT through 5 years after transplant

Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data

From start of alloHCT through 5 years after transplant
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
大体时间:From Orca-Q infusion through 5 years after transplant

Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded

From Orca-Q infusion through 5 years after transplant
Incidence of aGVHD
大体时间:From transplant through 5 years after transplant

Number of participants with aGVHD

From transplant through 5 years after transplant
Severity of aGVHD
大体时间:From transplant through 5 years after transplant

Severity is graded per MAGIC criteria

From transplant through 5 years after transplant
Incidence chronic graft-versus-host disease (cGVHD)
大体时间:From transplant through 5 years after transplant

Number of participants with cGVHD

From transplant through 5 years after transplant
Severity of cGVHD
大体时间:From transplant through 5 years after transplant

cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD

From transplant through 5 years after transplant
Incidence of Primary Graft Failure
大体时间:Through day +28

Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause

Through day +28
Incidence of Secondary Graft Failure
大体时间:Through day +100

Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause

Through day +100
Time to Neutrophil Engraftment
大体时间:From transplant through Day +365

Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days.

From transplant through Day +365
Development of Infectious Complications
大体时间:From transplant through Day +730 (2 years), with long-term follow-up through 5 years

Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation

From transplant through Day +730 (2 years), with long-term follow-up through 5 years
Regimen-Related Toxicity
大体时间:From start of conditioning through 1 year after transplant

Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse).

From start of conditioning through 1 year after transplant

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年3月1日

初级完成 (估计的)

2028年6月1日

研究完成 (估计的)

2032年12月1日

研究注册日期

首次提交

2025年2月3日

首先提交符合 QC 标准的

2025年3月26日

首次发布 (实际的)

2025年3月28日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅